AgomAb Therapeutics NV ADR Company Profile
NASDAQ: AGMBHealth CareBiotechnology: Biological Products (No Diagnostic Substances)USD
At close: Oct 8, 4:00 PM ET · Delayed 15 min
AgomAb Therapeutics NV at a glance
AgomAb Therapeutics NV ADR (NASDAQ: AGMB) is a Biotechnology: Biological Products (No Diagnostic Substances) company in the Health Care sector headquartered in Antwerp, Belgium. AgomAb Therapeutics NV is led by Dr. Tim Knotnerus MSc, Ph.D. and employs about 62 people. The company's shares have traded publicly since 2026.
At a market capitalization of $454.1 million, it is considered a small-cap company. Its SEC Central Index Key (CIK) is 0002020932, which identifies the company's filings on EDGAR.
Summary generated from market data by MetaCap's automated system. Methodology
What does AgomAb Therapeutics NV do?
AgomAb Therapeutics NV, a clinical-stage biopharmaceutical company, develops novel disease-modifying therapies for immunology and inflammatory diseases in the United States. The company's product pipeline includes Ontunisertib (AGMB-129), an oral gastrointestinal-restricted small molecule inhibitor of ALK5 or TGFßR1 for the treatment of Fibrostenosing Crohn's disease, which is in Phase 2a clinical trials; and AGMB-447, an inhaled small molecule inhibitor of ALK5 or TGFßR1 for the treatment of idiopathic pulmonary fibrosis that is in Phase 1 clinical trials. It also develops AGMB-101, a HGF-mimetic monoclonal antibody that acts through agonism or stimulation of the MET receptor and has demonstrated antifibrotic and regenerative activity in preclinical models. The company was incorporated in 2017 and is headquartered in Antwerp, Belgium.
Business description based on the company's public filings.
Company information
- Legal name
- AgomAb Therapeutics NV ADR
- Ticker
- NASDAQ: AGMB
- Sector
- Health Care
- Industry
- Biotechnology: Biological Products (No Diagnostic Substances)
- CEO
- Dr. Tim Knotnerus MSc, Ph.D.
- Employees
- 62
- Headquarters
- Posthoflei 1/6, Antwerp, Belgium
- Phone
- 32 3 318 91 70
- Website
- agomab.com
- IPO year
- 2026
- Market cap
- $454.07M
- SEC CIK
- 0002020932
Companies similar to AgomAb Therapeutics NV
| Company | Price | % Chg | Market cap | Compare |
|---|---|---|---|---|
| TECXTectonic Therapeutic Inc. | 22.75 | +0.18% | $444.75M | vs AGMB |
| AUTLAutolus Therapeutics plc ADR | 1.77 | -2.21% | $471.11M | vs AGMB |
| EDITEditas Medicine Inc. | 2.84 | +3.27% | $436.17M | vs AGMB |
| ENTXEntera Bio Ltd. | 2.50 | -0.40% | $434.59M | vs AGMB |
| ALLOAllogene Therapeutics Inc. | 1.40 | -2.10% | $483.69M | vs AGMB |
| EIKNEikon Therapeutics Inc. | 7.50 | -0.53% | $406.24M | vs AGMB |
| ZURAZura Bio Limited Class A | 4.13 | -0.96% | $395.77M | vs AGMB |
| KYTXKyverna Therapeutics Inc. | 6.18 | +0.16% | $382.19M | vs AGMB |